Waldencast plc(US:WALD) Globenewswire·2025-07-23 10:45Core Insights - Waldencast plc has acquired Novaestiq Corp, enhancing Obagi Medical's product portfolio with scientifically backed injectable products, positioning it as a leader in the health, beauty, and aesthetics convergence [1][2][6] - The acquisition allows Obagi Medical to expand into the U.S. dermal filler market, projected to reach $2 billion by 2029, effectively doubling its addressable market [1][2] - The Saypha line of hyaluronic acid injectable gels is currently undergoing FDA approval and is recognized for its safety and efficacy, supported by a robust clinical program [3][4] Company Strategy - Obagi Medical aims to integrate medical-grade skincare with aesthetic treatments, enhancing patient satisfaction and outcomes through a holistic, science-driven approach [2][5] - The company is focused on becoming the 1 Dermatological Mega Brand, leveraging a strategy that includes dermatological science, breakthrough innovations, and global expansion [5][6] - The acquisition is expected to create new growth opportunities and strengthen Obagi Medical's market position in the fast-evolving beauty and wellness industry [6] Product Details - Saypha products utilize proprietary technology for advanced HA treatments, ensuring natural-looking results and optimal gel characteristics [4] - The portfolio is backed by extensive clinical studies, emphasizing effectiveness across diverse skin types and tones [3][4] - The acquisition provides access to a future pipeline of novel injectables in North America, further diversifying Obagi Medical's offerings [2][3] Transaction Overview - The acquisition involves cash payments, ongoing royalties based on net sales of Saypha products, and contingent issuance of Waldencast class A shares based on FDA approval and revenue milestones [7] - The transaction reflects Waldencast's commitment to building a multi-brand beauty and wellness platform, enhancing operational scale and market responsiveness [8]